Week 5 Draft 3

ML385 would be another great inhibitor to use to target the trans activation of NRF2, transcription factor. This all works by ML385 finding a potential binding domain within NRF2 and in these case it will be the cap and collar or Neh1. Neh1 is also a region in which DNA binding occurs. Once it finds the potential binding domain it doesn't allow for the binding of the Nrf2-MAFG complex to ARE. MAFG is just a kind of sMaf, which are basic regions for leucine zipper type transcription factors. They act on gene regulation. This all results in a decrease in the rate of transcriptional activity.  In a Keap1 mutation it will result in the levels of GSH being reduced and GSH is composed of cysteine, glutamate and glycine.